Other therapeutic strategies such as the use of alpha lipoic acid or erythropoietin have been shown to inhibit TGF-β induced extracellular matrix accumulation in diabetic cardiomyopathy [47,66]. The gene discussed is TGFB1; the disease is diabetic cardiomyopathy.